JP5072367B2 - 神経変性疾患の処置における亜塩素酸 - Google Patents

神経変性疾患の処置における亜塩素酸 Download PDF

Info

Publication number
JP5072367B2
JP5072367B2 JP2006552151A JP2006552151A JP5072367B2 JP 5072367 B2 JP5072367 B2 JP 5072367B2 JP 2006552151 A JP2006552151 A JP 2006552151A JP 2006552151 A JP2006552151 A JP 2006552151A JP 5072367 B2 JP5072367 B2 JP 5072367B2
Authority
JP
Japan
Prior art keywords
als
disease
patients
macrophage
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2006552151A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007520554A (ja
Inventor
マイケル エス． マクグラス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California, Los Angeles
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34860199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5072367(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of JP2007520554A publication Critical patent/JP2007520554A/ja
Application granted granted Critical
Publication of JP5072367B2 publication Critical patent/JP5072367B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2006552151A 2004-02-03 2005-01-25 神経変性疾患の処置における亜塩素酸 Expired - Lifetime JP5072367B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54157604P 2004-02-03 2004-02-03
US60/541,576 2004-02-03
PCT/US2005/002469 WO2005076819A2 (en) 2004-02-03 2005-01-25 Chlorite in the treatment of neurodegenerative disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011233850A Division JP5797083B2 (ja) 2004-02-03 2011-10-25 神経変性疾患の処置における亜塩素酸

Publications (2)

Publication Number Publication Date
JP2007520554A JP2007520554A (ja) 2007-07-26
JP5072367B2 true JP5072367B2 (ja) 2012-11-14

Family

ID=34860199

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006552151A Expired - Lifetime JP5072367B2 (ja) 2004-02-03 2005-01-25 神経変性疾患の処置における亜塩素酸
JP2011233850A Expired - Lifetime JP5797083B2 (ja) 2004-02-03 2011-10-25 神経変性疾患の処置における亜塩素酸
JP2015118841A Pending JP2015205901A (ja) 2004-02-03 2015-06-12 神経変性疾患の処置における亜塩素酸

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011233850A Expired - Lifetime JP5797083B2 (ja) 2004-02-03 2011-10-25 神経変性疾患の処置における亜塩素酸
JP2015118841A Pending JP2015205901A (ja) 2004-02-03 2015-06-12 神経変性疾患の処置における亜塩素酸

Country Status (7)

Country Link
US (5) US7105183B2 (enExample)
EP (2) EP1711191B1 (enExample)
JP (3) JP5072367B2 (enExample)
CN (2) CN102423318B (enExample)
AU (1) AU2005213300B2 (enExample)
CA (2) CA2838392C (enExample)
WO (1) WO2005076819A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012067110A (ja) * 2004-02-03 2012-04-05 Regents Of The Univ Of California 神経変性疾患の処置における亜塩素酸

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002343609B2 (en) * 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
WO2006009506A1 (en) * 2004-07-16 2006-01-26 Gyros Patent Ab Sequential method
MX2007013985A (es) 2005-05-09 2008-02-22 Theranos Inc Sistemas de fluidos de punto de cuidado y usos de los mismos.
DK1915620T3 (da) * 2005-08-02 2010-10-04 Xbiotech Inc Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
US8067035B2 (en) 2005-12-22 2011-11-29 Neuraltus Pharmaceuticals, Inc. Chlorite formulations, and methods of preparation and use thereof
AU2013234421B2 (en) * 2005-12-22 2015-08-27 Neuraltus Pharmaceuticals, Inc. Chlorite formulations, and methods of preparation and use thereof
US11287421B2 (en) 2006-03-24 2022-03-29 Labrador Diagnostics Llc Systems and methods of sample processing and fluid control in a fluidic system
US8741230B2 (en) 2006-03-24 2014-06-03 Theranos, Inc. Systems and methods of sample processing and fluid control in a fluidic system
US8007999B2 (en) * 2006-05-10 2011-08-30 Theranos, Inc. Real-time detection of influenza virus
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
CN102580086A (zh) * 2006-05-22 2012-07-18 埃克斯生物科技公司 使用抗IL-1α抗体治疗癌症
US20080113391A1 (en) 2006-11-14 2008-05-15 Ian Gibbons Detection and quantification of analytes in bodily fluids
FR2910811B1 (fr) * 2007-01-03 2009-07-10 Ass Pour Le Dev De La Biothera Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments
US8158430B1 (en) 2007-08-06 2012-04-17 Theranos, Inc. Systems and methods of fluidic sample processing
HUE029003T2 (en) * 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
JP5976319B2 (ja) * 2008-09-12 2016-08-23 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 病原性単球の標的化
EA201290041A1 (ru) * 2009-08-06 2012-07-30 Ньюралтус Фармасьютикалс, Инк. Лечение расстройств, связанных с макрофагами
AU2010308329B2 (en) 2009-10-19 2016-10-13 Labrador Diagnostics Llc Integrated health data capture and analysis system
EP2545381A1 (en) * 2010-03-10 2013-01-16 Yeda Research And Development Co. Ltd. Cellular blood markers for early diagnosis of als and for als progression
CN102946904A (zh) 2010-06-18 2013-02-27 埃克斯生物科技公司 关节炎治疗
KR101847669B1 (ko) * 2010-08-16 2018-05-24 알러간, 인코포레이티드 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법
PH12013500316A1 (en) 2010-08-23 2016-09-02 Janssen Biotech Inc Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
PT2750709T (pt) 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
RU2014130080A (ru) 2011-12-22 2016-02-10 Нуво Рисерч Гмбх Липосомальные композиции хлоритов или хлоратов
CN107759690A (zh) * 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CA2945179A1 (en) * 2014-05-16 2015-11-19 Michael S. Mcgrath Methods and compositions for treatment of macrophage-related disorders
EP3072513A1 (en) * 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
EP3370738A2 (en) 2015-11-02 2018-09-12 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
JP7145162B2 (ja) 2017-02-16 2022-09-30 ヤンセン バイオテク，インコーポレイテッド 化膿性汗腺炎の処置
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
JP2024533873A (ja) 2021-10-04 2024-09-12 ニューヴィヴォ， インコーポレイテッド Ａｌｓ患者の処置方法
JP2025518546A (ja) * 2022-05-19 2025-06-17 ニューヴィヴォ， インコーポレイテッド 神経変性疾患のバイオマーカー
US20250114396A1 (en) * 2023-07-07 2025-04-10 The Regents Of The University Of California Chlorite uses for stem cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3213389A1 (de) * 1982-04-10 1983-10-20 Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten
US4576945A (en) * 1982-10-26 1986-03-18 Sanders Mark E Hexaalkylmelamine-amino-oxy compounds
DE3515745A1 (de) 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Waessrige chloritmatrix-loesung
US5051414A (en) * 1989-08-03 1991-09-24 Dupont Merck Pharmaceutical Company Inhibition of HIV and other retroviruses by polyoxoanions
DE4208828A1 (de) 1992-03-19 1993-09-23 Oxo Chemie Gmbh Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen
US6099855A (en) * 1992-06-25 2000-08-08 Bioxy, Inc. Therapeutic, production and immunostimulatory uses of biocidal compositions
US5855922A (en) * 1995-12-07 1999-01-05 Bio-Cide International, Inc. Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders
US5877222A (en) 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
AU754928B2 (en) 1997-10-06 2002-11-28 Oxo Chemie Ag Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
JP2001078775A (ja) * 1999-09-14 2001-03-27 Kokuritsu Seishin Shinkei Center マクロファージ機能調節剤
US20040224306A1 (en) * 1999-11-30 2004-11-11 Frederich-Wilhelm Kuhne Evaluating and predicting clinical outcomes by gene expression analysis
US6685754B2 (en) 2001-03-06 2004-02-03 Alchemix Corporation Method for the production of hydrogen-containing gaseous mixtures
AU2002343609B2 (en) 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012067110A (ja) * 2004-02-03 2012-04-05 Regents Of The Univ Of California 神経変性疾患の処置における亜塩素酸

Also Published As

Publication number Publication date
US20060159775A1 (en) 2006-07-20
US20170065634A1 (en) 2017-03-09
CA2554511C (en) 2016-01-19
CN102423318B (zh) 2015-09-09
US8029826B2 (en) 2011-10-04
EP1711191A2 (en) 2006-10-18
JP2012067110A (ja) 2012-04-05
EP2574342B1 (en) 2018-03-07
WO2005076819A2 (en) 2005-08-25
CA2838392A1 (en) 2005-08-25
US20110053186A1 (en) 2011-03-03
CA2554511A1 (en) 2005-08-25
AU2005213300A1 (en) 2005-08-25
JP2007520554A (ja) 2007-07-26
WO2005076819A3 (en) 2006-04-13
US20120295296A1 (en) 2012-11-22
US9364501B2 (en) 2016-06-14
EP1711191A4 (en) 2008-12-17
CN101102781B (zh) 2012-06-20
CA2838392C (en) 2017-04-04
JP2015205901A (ja) 2015-11-19
EP2574342A1 (en) 2013-04-03
AU2005213300B2 (en) 2011-06-16
CN102423318A (zh) 2012-04-25
US20050181068A1 (en) 2005-08-18
EP1711191B1 (en) 2014-03-19
CN101102781A (zh) 2008-01-09
US7105183B2 (en) 2006-09-12
JP5797083B2 (ja) 2015-10-21

Similar Documents

Publication Publication Date Title
JP5797083B2 (ja) 神経変性疾患の処置における亜塩素酸
US11938148B2 (en) Treatment of neurodegenerative disease with sodium chlorite
EP3142674A1 (en) Methods and compositions for treatment of macrophage-related disorders
AU2014203207B2 (en) Chlorite in the treatment of neurodegenerative disease
Hagihara et al. Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus
Ahmad et al. Substance P concentration in saliva of patients who report dental pain
Huwe et al. 119: Effect of Epididymitis on Semen Biochemical and Sperm Morphology Parameters

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110726

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111025

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120711

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120719

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120813

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120821

R150 Certificate of patent or registration of utility model

Ref document number: 5072367

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150831

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term